2019
DOI: 10.1038/s41581-019-0199-3
|View full text |Cite
|
Sign up to set email alerts
|

Prognostic and predictive enrichment in sepsis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
152
0
5

Year Published

2020
2020
2023
2023

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 194 publications
(157 citation statements)
references
References 115 publications
0
152
0
5
Order By: Relevance
“…Despite the association with adverse outcome, the accuracy of low mHLA-DR expression to predict clinical outcome at the individual patient level was limited in our cohort. That said, considering the amount of literature associating low mHLA-DR and unfavourable outcomes, it remains a valuable marker for enrichment in clinical trials, for example to select a group of patients that may benefit from immunomodulating therapies [25,26]. Nevertheless, in light of the fact that septic shock is a highly complex immunological syndrome, involving multiple immune defects that vary between patients and within patients over time [27], it remains debatable whether a single biomarker will ever be sufficient to gauge a patient's overall immune status.…”
Section: Discussionmentioning
confidence: 99%
“…Despite the association with adverse outcome, the accuracy of low mHLA-DR expression to predict clinical outcome at the individual patient level was limited in our cohort. That said, considering the amount of literature associating low mHLA-DR and unfavourable outcomes, it remains a valuable marker for enrichment in clinical trials, for example to select a group of patients that may benefit from immunomodulating therapies [25,26]. Nevertheless, in light of the fact that septic shock is a highly complex immunological syndrome, involving multiple immune defects that vary between patients and within patients over time [27], it remains debatable whether a single biomarker will ever be sufficient to gauge a patient's overall immune status.…”
Section: Discussionmentioning
confidence: 99%
“…To date, they have not been used as prognostic or predictive tools in contemporary clinical trials. In addition, unidimensional markers (e.g., IL-6, pro-calcitonin) have failed to confer prognostic classification in RCTs evaluating other ICU-related pathologies, such as sepsis or ARDS [63]. There is a pressing need for alternative approaches that can be exploited to better understand and monitor the biological mechanisms related to nutritional risk and metabolic heterogeneity.…”
Section: Systemic Markers Of Inflammationmentioning
confidence: 99%
“…Once reduced to biomarker panels, analytes derived from transcriptomic and epigenomic metadata can be tested in multiplex PCR-based panels [85]. The measurement of whole blood or peripheral blood mononuclear cell mRNA levels can be implemented in the clinical setting and in the context of RCTs [63]. Technologies for the standardized measurement of DNA or RNA are available in clinical laboratories or as point-of-care tests.…”
Section: Assessment Of Mrna Levels and Epigenetic Modificationsmentioning
confidence: 99%
“…3 The awareness and early recognition of sepsis sources in all clinical practice subsets is the foundation of successful management of sepsis also by bioinformatics and precision medicine. [29][30][31][32][33][34] Increasing bioinformatics literacy by e-learning is a well established strategy. 35 A key point is that the low cost of UltraSound machines makes such investments affordable even in limited-resources settings.…”
Section: Advice and Sustainable Actionsmentioning
confidence: 99%